Emmaus Life Sciences

EMMA · OTCQB · United States

Public Market Listing

EMMAOTCQB

OTCQB primary exchange listing

Live quotes, historical charts, and market capitalization for Emmaus Life Sciences are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Amino AcidSmall molecule
Sickle Cell Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 June 2025ApprovalL-glutamine (Endari)FDA approves Endari label changes
US, FDA · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$6.3M$0.1M$2.8M—$1.7M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$2.0M<$0.1M$1.1M$3.3M-$0.3M operating cash flowreport ↗
2025-Q3$3.4M$0.1M$0.3M$2.1M$0.4M operating cash flowreport ↗
2025-Q2$2.8M$0.1M$0.9M$1.1M-$2.9M operating cash flowreport ↗
2025-Q1$2.4M$0.2M$1.3M$2.3M$0.3M operating cash flowreport ↗
2024-Q3$5.5M$0.1M$1.3M—$0.1M operating cash flowreport ↗
2024-Q2$5.4M$0.2M$1.5M$2.2M-$2.9M operating cash flowreport ↗
2024-Q1$2.5M$0.2M$1.7M$4.3M$0.1M operating cash flowreport ↗
2023-Q3$5.0M$0.4M$1.5M—$0.1M operating cash flowreport ↗
2023-Q2$11M$0.3M$1.4M$1.5M-$1.3M operating cash flowreport ↗
2023-Q1$6.8M$0.3M$1.8M$3.5M-$1.3M operating cash flowreport ↗
2022-Q3$4.9M$0.4M$1.2M$0.4M-$0.9M operating cash flowreport ↗
2022-Q2$4.3M$0.3M$1.0M$8.9M-$1.1M operating cash flowreport ↗
2022-Q1$3.2M$0.5M$0.8M$1.5M-$4.7M operating cash flowreport ↗
2021-Q3$5.8M$0.5M$2.3M$3.1M$1.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$12M$0.3M$2.1M$1.9M-<$0.1M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$17M$0.7M$1.4M$1.6M-$2.3M operating cash flowreport ↗
2023-FY$30M$1.2M$2.5M$0.9M-$1.5M operating cash flowreport ↗
2022-FY$18M$1.7M$2.0M$2.7M-$5.1M operating cash flowreport ↗
2021-FY$21M$4.1M$2.3M$4.0M-$1.3M operating cash flowreport ↗